Activity of Distamycin A on Vaccinia Virus Infection of Cell Cultures

Chemotherapy ◽  
1964 ◽  
Vol 9 (3) ◽  
pp. 144-157 ◽  
Author(s):  
M.A. Verini ◽  
M. Ghione
Keyword(s):  
Virus Infection ◽  
Vaccinia Virus ◽  
Cell Cultures ◽  
Distamycin A ◽  
Vaccinia Virus Infection

scholarly journals Vaccinia Virus Infection in Monkeys, Brazilian Amazon

2010 ◽  
Vol 16 (6) ◽  
pp. 976-979 ◽  
Author(s):  
Jônatas S. Abrahão ◽  
André T. Silva-Fernandes ◽  
Larissa S. Lima ◽  
Rafael K. Campos ◽  
Maria I.M.C. Guedes ◽  
...  
Keyword(s):  
Virus Infection ◽  
Vaccinia Virus ◽  
Brazilian Amazon ◽  
Vaccinia Virus Infection

H–2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection

Nature ◽  
1976 ◽  
Vol 259 (5540) ◽  
pp. 228-230 ◽  
Author(s):  
FEDERICO GARRIDO ◽  
VOLKER SCHIRRMACHER ◽  
HILLIARD FESTENSTEIN
Keyword(s):  
Virus Infection ◽  
Vaccinia Virus ◽  
Vaccinia Virus Infection ◽  
Mouse Sarcoma

scholarly journals 1207. Vaccinia Virus Infection Acquired from an Occupational Needlestick—San Diego, California, 2019

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S434-S434
Author(s):  
Erin R Whitehouse ◽  
Agam Rao ◽  
Yon Yu ◽  
Patricia Yu ◽  
Margaret Griffin ◽  
...  
Keyword(s):  
Virus Infection ◽  
Vaccinia Virus ◽  
Treatment Decisions ◽  
Left Index Finger ◽  
Severe Illness ◽  
Local Health ◽  
Health Clinics ◽  
Vaccinia Virus Infection ◽  
Medication Access ◽  
Specific Strain

Abstract Background Vaccinia virus, a virus similar to but less virulent than variola virus, is a component of smallpox vaccines and increasingly used for medical research. Vaccinia immunoglobulin intravenous (VIGIV) and tecovirimat are stockpiled in the U.S. Strategic National Stockpile (SNS) for potential smallpox bioterror events, but only VIGIV is licensed for vaccinia treatment. On January 12, 2019, CDC was consulted for worsening infection in a laboratory worker after a needlestick with vaccinia. Methods We investigated demographic, clinical, vaccination, and exposure history and determined likelihood of vaccinia virus infection. Identity of the specific strain was sought because some have genetic modifications that might impact virulence. Discussions among stakeholders informed treatment decisions and facilitated medication access and usage. Swabs from the lesion were tested by real-time polymerase chain reaction for orthopoxvirus DNA, which includes vaccinia. Results The affected worker was an otherwise healthy 26-year-old woman who developed a pustular lesion at the needlestick site on her left index finger (Image). The patient had been injecting vaccinia virus into a mouse and had declined nationally recommended vaccination. Edema, lymphadenopathy, and fever raised concern for severe illness; neither the patient nor occupational health were certain of the vaccinia strain type. CDC, SNS, local health departments, drug manufacturers, and clinicians rapidly collaborated to make treatment decisions based on available information and ensure delivery of both biologics and administration of tecovirimat under an expanded access investigational new drug protocol. Eventually, a wound swab tested positive and the strain was determined to be one with no known impact on virulence. Conclusion With increasing use of vaccinia in research, occupational infections may continue to occur. Health clinics should extensively counsel staff who decline vaccination and have documentation on-hand about vaccinia virus types to inform treatment decisions. This response prompted CDC to develop outreach materials specifically for occupational vaccinia exposures. Disclosures All authors: No reported disclosures.

A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia-virus infection

2005 ◽  
Vol 41 (1) ◽  
pp. 59 ◽  
Author(s):  
Dania M. Vázquez-Blomquist ◽  
Diógenes Quintana-Vázquez ◽  
Ernesto Galbán Rodríguez ◽  
Antonieta M. Herrera Buch ◽  
Carlos A. Duarte Cano
Keyword(s):  
Virus Infection ◽  
Vaccinia Virus ◽  
Semliki Forest Virus ◽  
Vaccination Strategy ◽  
Fowlpox Virus ◽  
Vaccinia Virus Infection ◽  
Hiv 1

Actinomycin D and Vaccinia Virus Infection of Hela Cells

Nature ◽  
1963 ◽  
Vol 199 (4891) ◽  
pp. 357-358 ◽  
Author(s):  
AARON J. SHATKIN
Keyword(s):  
Virus Infection ◽  
Vaccinia Virus ◽  
Hela Cells ◽  
Actinomycin D ◽  
Vaccinia Virus Infection
Sign in / Sign up

Export Citation Format

Share Document